NASDAQ:XLO - Nasdaq - US98422T1007 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to XLO. XLO was compared to 567 industry peers in the Biotechnology industry. The financial health of XLO is average, but there are quite some concerns on its profitability. XLO does not seem to be growing, but still is valued expensively.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -81.94% | ||
ROE | -330.95% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -9.25 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.21 | ||
Quick Ratio | 2.21 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.7502
0 (-0.64%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 6.12 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 2.21 | ||
P/tB | 2.21 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -81.94% | ||
ROE | -330.95% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 2.19% | ||
Cap/Sales | 0.57% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.21 | ||
Quick Ratio | 2.21 | ||
Altman-Z | -9.25 |